RESUMO
We present a design for the experimental integration of ion trapping and superconducting qubit systems as a step towards the realization of a quantum hybrid system. The scheme addresses two key difficulties in realizing such a system: a combined microfabricated ion trap and superconducting qubit architecture, and the experimental infrastructure to facilitate both technologies. Developing upon work by Kielpinski et al. (Phys Rev Lett 108(13):130504, 2012. doi:10.1103/PhysRevLett.108.130504), we describe the design, simulation and fabrication process for a microfabricated ion trap capable of coupling an ion to a superconducting microwave LC circuit with a coupling strength in the tens of kHz. We also describe existing difficulties in combining the experimental infrastructure of an ion trapping set-up into a dilution refrigerator with superconducting qubits and present solutions that can be immediately implemented using current technology.
RESUMO
The setting for this retrospective cohort study was a specialised tuberculosis unit in Madrid, Spain. The objective was to describe the risk factors for multidrug-resistant tuberculosis (MDR-TB). The medical records of all patients admitted to the unit were reviewed retrospectively to identify factors associated with multidrug resistance. Patients with positive culture for M. tuberculosis and with available drug-susceptibility tests were included. The variables assessed were age, gender, country of origin, homelessness, alcohol consumption, intravenous drug use, methadone substitution therapy, contact with a tuberculosis patient, sputum smear, site of disease, previous tuberculosis treatment, HIV infection, history of imprisonment, diabetes mellitus and chronic obstructive pulmonary disease. Thirty patients with MDR-TB and 666 patients with non-MDR-TB were included from the years 1997 to 2006. The only factors associated with MDR-TB in multivariate analysis were previous tuberculosis treatment (OR: 3.44; 95% CI: 1.58-7.50; p = 0.003), age group 45-64 years (OR: 3.24; 95% CI: 1.34-7.81; p = 0.009) and alcohol abuse (OR: 0.12; 95% CI: 0.03 to 0.55; p = 0.003). In our study, patients who had had previous treatment for tuberculosis, who were 45-64 years of age or who had no history of alcohol abuse were more likely to have MDR-TB.
Assuntos
Farmacorresistência Bacteriana Múltipla , Mycobacterium tuberculosis/efeitos dos fármacos , Fatores de Risco , Tuberculose Resistente a Múltiplos Medicamentos/epidemiologia , Adolescente , Adulto , Fatores Etários , Idoso , Idoso de 80 Anos ou mais , Alcoolismo , Distribuição de Qui-Quadrado , Estudos de Coortes , Feminino , Hospitais de Doenças Crônicas , Humanos , Masculino , Pessoa de Meia-Idade , Análise Multivariada , Mycobacterium tuberculosis/isolamento & purificação , Estudos Retrospectivos , Espanha , Tuberculose/tratamento farmacológico , Tuberculose/epidemiologia , Tuberculose/microbiologia , Tuberculose Resistente a Múltiplos Medicamentos/microbiologiaRESUMO
Rifampicin is an essential drug in the present treatment of tuberculosis. On some occasions, it cannot be used due to severe adverse effects. Rifabutin is a drug of the same family, with a similar activity and difference adverse effects. This study describes the beneficial results of the substitution of rifampicin with rifabutin in patients with severe toxicity.
Assuntos
Antibióticos Antituberculose/efeitos adversos , Antibióticos Antituberculose/uso terapêutico , Rifabutina/uso terapêutico , Rifampina/efeitos adversos , Tuberculose/tratamento farmacológico , Adulto , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-IdadeRESUMO
La rifampicina es un fármaco esencial en el tratamiento actual de la tuberculosis. En algunas ocasiones no se puede utilizar por efectos adversos graves. La rifabutina es un fármaco de la misma familia, con una actividad similar y efectos adversos diferentes. En este estudio se describen los resultados beneficiosos de la sustitución de rifampicina por rifabutina en pacientes con toxicidad intensa (AU)
Rifampicin is an essential drug in the present treatment of tuberculosis. On some occasions, it cannot be used due to severe adverse effects. Rifabutin is a drug of the same family, with a similar activity and difference adverse effects. This study describes the beneficial results of the substitution of rifampicin with rifabutin in patients with severe toxicity (AU)
Assuntos
Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Humanos , Rifabutina/farmacocinética , Rifampina/efeitos adversos , Tuberculose Pulmonar/tratamento farmacológico , Estudos Retrospectivos , Infecções por HIV/complicações , Mycobacterium tuberculosisRESUMO
Recientemente se ha propuesto la utilización de aciclovir en el tratamiento de la parálisis facial idiopática, debido al auge que la hipótesis vírica ha tenido en los últimos años. Varios ensayos clínicos han intentado demostrar la utilidad del uso combinado de aciclovir y prednisona frente al uso de prednisona sola. Revisamos la literatura con el fin de establecer pautas de actuación en Atención Primaria y concluimos que con los datos disponibles en la actualidad no existe evidencia suficiente para recomendar el uso de aciclovir en el tratamiento de la parálisis facial idiopática (AU)
Assuntos
Humanos , Aciclovir/uso terapêutico , Antivirais/uso terapêutico , Paralisia de Bell/tratamento farmacológico , Prednisona/uso terapêutico , Quimioterapia Combinada , Glucocorticoides/uso terapêuticoRESUMO
No disponible
Assuntos
Adulto , Feminino , Humanos , Bursite/diagnóstico , Lúpus Eritematoso Sistêmico/diagnóstico , Lúpus Eritematoso Sistêmico/tratamento farmacológico , Diagnóstico DiferencialRESUMO
No disponible
Assuntos
Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Tomografia Computadorizada por Raios X , Trombose Venosa , Adenocarcinoma , Neoplasias PancreáticasRESUMO
No disponible
Assuntos
Pessoa de Meia-Idade , Adulto , Feminino , Humanos , Tuberculose Laríngea , Distúrbios da VozRESUMO
No disponible
